Abstract
This chapter provides the background for understanding the current status of progress towards establishing nuclear magnetic resonance (NMR), applied as magnetic resonance imaging (MRI) and localized spectroscopy or spectroscopic imaging (MRS, MRSI), as a viable method for the noninvasive, in vivo imaging of compounds used in BNCT. The underlying physical principles are presented, and the progress is reviewed, covering not only the direct detection of Boron (10B or 11B), but also other nuclear species in the BNCT agents that are amenable for NMR detection.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bendel P (2005) Biomedical applications of 10B and 11B NMR. NMR Biomed 18:74–82
Bendel P, Sauerwein W (2001) Optimal detection of the neutron capture therapy agent borocaptate sodium (BSH): a comparison between 1H and 10B NMR. Med Phys 28:178–183
Bendel P, Zilberstein J, Salomon Y (1994) In vivo detection of a boron neutron capture therapy agent in melanoma by proton observed 1H-10B double resonance. Magn Reson Med 32:170–174
Bendel P, Zilberstein J, Salomon Y, Frantz A, Reddy NK, Kabalka GW (1997) Quantitative in vivo NMR detection of BSH and 19F-BPA in a mouse melanoma model. In: Larsson B, Crawford J, Weinreich R (eds) Advances in neutron capture therapy, vol II, Chemistry and biology. Elsevier, Amsterdam
Bendel P, Frantz A, Zilberstein J, Kabalka GW, Salomon Y (1998) Boron-11 NMR of borocaptate: relaxation and in vivo detection in melanoma-bearing mice. Magn Reson Med 39:439–447
Bendel P, Koudinova N, Salomon Y (2001) In vivo imaging of the neutron capture therapy agent BSH in mice using 10B MRI. Magn Reson Med 46:13–17
Bendel P, Koudinova N, Salomon Y, Hideghéty K, Sauerwein W (2002) Imaging of BSH by 10B MRI. In: Sauerwein W, Moss R, Wittig A (eds) Research and development in neutron capture therapy. Monduzzi, Bologna
Bendel P, Margalit R, Koudinova N, Salomon Y (2005) Noninvasive quantitative in vivo mapping and metabolism of boronophenylalanine (BPA) by nuclear magnetic resonance (NMR) spectroscopy and imaging. Rad Res 164:680–687
Bendel P, Margalit R, Salomon Y (2005) Optimized 1H MRS and MRSI methods for the in vivo detection of boronophenylalanine. Magn Reson Med 53:1166–1171
Bradshaw KM, Schweizer MP, Glover GH, Hadley JR, Tippets R, Tang PP, Davis WL, Heilbrun MP, Johnson S, Ghanem T (1995) BSH distributions in the canine head and a human patient using 11B MRI. Magn Reson Med 34:48–56
Callaghan PT (1993) Principles of nuclear magnetic resonance microscopy. Clarendon, Oxford
Capuani S, Porcari P, Fasano F, Campanella R, Maraviglia B (2008) 10B-editing 1H-detection and 19F MRI strategies to optimize boron neutron capture therapy. Mag Res Imag 26:987–993
De Luca F, Campanella R, Bifone A, Maraviglia B (1991) Boron-10 double resonance spatial NMR detection. Chem Phys Lett 186:303–306
Hofmann B, Fischer CO, Lawaczeck R, Platzek J, Semmler W (1999) Gadolinium neutron capture therapy (GdNCT) of melanoma cells and solid tumors with the magnetic resonance imaging contrast agent Gadobutrol. Invest Radiol 34:126–133
Hoult DI, Lauterbur PC (1979) The sensitivity of the zeugmatographic experiment involving human samples. J Magn Reson 34:425–433
Hoult DI, Richards RE (1976) The signal-to-noise ratio of the nuclear magnetic resonance experiment. J Magn Reson 24:71–85
Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, Ido T (1998) Fluorine-18 labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 39:325–333
Kabalka GW, Davis M, Bendel P (1988) Boron-11 MRI and MRS of intact animals infused with a boron neutron capture therapy agent. Magn Reson Med 8:231–237
Nakamura H, Fukuda H, Girald F, Kobayashi T, Hiratsuka J, Akaizawa T, Nemoto H, Cai J, Yoshida K, Yamamoto Y (2000) In vivo evaluation of carborane gadolinium-DPTA complex as an MR imaging boron carrier. Chem Pharm Bull 48:1034–1038
Nichols TL, Kabalka GW, Miller LF, Khan MK, Smith GT (2002) Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography. Med Phys 29:2351–2358
Panov V, Salomon Y, Kabalka GW, Bendel P (2000) Uptake and washout of borocaptate sodium and borono-phenylalanine in cultured melanoma cells: a multi-nuclear NMR study. Rad Res 154:104–112
Porcari P, Capuani S, D’Amore E, Lecce M, La Bella A, Fasano F, Campanella R, Migneco LM, Pastore FS, Maraviglia B (2008) In vivo 19F MRI and 19F MRS of 19F-labelled boronophenylalanine–fructose complex on a C6 rat glioma model to optimize boron neutron capture therapy (BNCT). Phys Med Biol 53:6979–6989
Tatham AT, Nakamura H, Wiener EC, Yamamoto Y (1999) Relaxation properties of a dual-labeled probe for MRI and neutron capture therapy. Magn Reson Med 42:32–36
Zuo CS, Prasad PV, Busse P, Tang L, Zamenhof RG (1999) Proton nuclear magnetic resonance measurement of p-boronophenylalanine (BPA): a therapeutic agent for boron neutron capture therapy. Med Phys 26:1230–1236
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bendel, P. (2012). Boron Imaging: Localized Quantitative Detection and Imaging of Boron by Magnetic Resonance. In: Sauerwein, W., Wittig, A., Moss, R., Nakagawa, Y. (eds) Neutron Capture Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-31334-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-31334-9_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-31333-2
Online ISBN: 978-3-642-31334-9
eBook Packages: MedicineMedicine (R0)